EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis

Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu und 2 weitere

Clinical and Molecular Hepatology · 2026

DOI: 10.3350/cmh.2025.0528 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Juhee Ahn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Data Science, College of Intelligent Software Convergence, University of Suwon, Hwaseong, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Aspirin, Liver Neoplasms, Fatty Liver. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Association for the Study of the Liver, Korean Liver Foundation, Dong-A ST Co..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The association between aspirin use and hepatocellular carcinoma (HCC) risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. This study evaluated the effect of aspirin on HCC development in MASLD patients using Korean National Health Insurance Service (NHIS) and UK Biobank (UKB) databases.

Methods

A retrospective cohort analysis was conducted using the NHIS database with a 3-year landmark design. Baseline characteristics were balanced using inverse probability of treatment weighting (IPTW) and 1:3 propensity score matching (PSM). Additionally, Mendelian randomization analysis was performed in the UKB cohort using a genomic risk score (GRS) for salicylic acid, based on genetic variants related to aspirin metabolism, as a proxy for aspirin use.

Results

In the NHIS cohort, 6,584,155 eligible patients were included, of whom 1,723,435 had MASLD. After PSM, aspirin use was associated with a significantly lower risk of HCC compared to no aspirin use, in both the overall population (adjusted subdistribution hazard ratio [ASHR]=0.86; 95% confidence interval [CI] 0.78–0.95; P=0.002) and MASLD group (ASHR=0.86; 95% CI 0.75–0.99; P=0.036). Similar results were reproduced in the IPTW population and several sensitivity and subgroup analyses. In the UKB cohort, individuals in the top 95% of GRS had a significantly lower risk of HCC compared to those in the bottom 5%, in both the overall population (ASHR=0.61; 95% CI 0.39–0.95; P=0.028) and MASLD group (ASHR=0.47; 95% CI 0.29–0.76; P=0.002).

Conclusions

Findings from both population-based and genetic analyses suggest a possible protective association between aspirin use and HCC in patients with MASLD, which warrants further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAspirinLiver NeoplasmsFatty LiverHumansMaleFemaleMiddle AgedRetrospective StudiesRisk FactorsAgedRepublic of KoreaMendelian Randomization AnalysisPolymorphism, Single NucleotideDatabases, FactualAdult

Stichwörter der Autor:innen

AspirinFatty liverLiver cancerSalicylic acidUK Biobank

Substanzen

Aspirin

Autor:innen und Institutionen

  • Division of Data Science, College of Intelligent Software Convergence, University of Suwon, Hwaseong, Korea.
  • Institute of Health and Environment, Seoul National University, Seoul, Korea.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Korea.
  • RexSoft Inc., Seoul, Korea.

Förderung

  • Korean Association for the Study of the Liver
  • Korean Liver Foundation
  • Dong-A ST Co.
  • Yuhan Corporation
  • Samjin Pharmaceuticals
  • Yuhan Pharmaceuticals
  • GreenCross Cell
  • Daewoong Pharmaceuticals

Zitieren

APA

Ahn, J., Hur, M. H., Shin, H., Park, M. K., Won, S., Park, J., Ko, Y., Park, Y., Lee, Y. B., Cho, E. J., Lee, J. H., Yu, S. J., Yoon, J. H., & Kim, Y. J. (2026). Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0528

Vancouver

Ahn J, Hur MH, Shin H, Park MK, Won S, Park J, et al. Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.0528

BibTeX
@article{Ahn2026,
  author = {Ahn, Juhee and Hur, Moon Haeng and Shin, Hyunjae and Park, Min Kyung and Won, Sungho and Park, Jeayeon and Ko, Yunmi and Park, Youngsu and Lee, Yun Bin and Cho, Eun Ju and Lee, Jeong-Hoon and Yu, Su Jong and Yoon, Jung-Hwan and Kim, Yoon Jun},
  title = {Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2025.0528}
}
Kostenlos starten →